Mood Disorders

Long-term safety and maintenance of response with esketamine nasal spray in treatment-resistant depression: final results of the SUSTAIN-3 study

In a long-term study (up to 6.6 years) of intermittently-dosed esketamine with daily antidepressant, early improvement in depression was maintained and no new safety signal was identified...

10/26/2023

Improvements in Depressive Symptoms in Patients With Major Depressive Disorder: Analysis of Zuranolone Efficacy From 4 Randomized, Placebo-Controlled Trials

An analysis of 4 randomized, placebo-controlled trials evaluating a 14-day treatment course of zuranolone 30- or 50-mg in adults with MDD showed nominally significant improvements (p ...

Anita H. Clayton , MD;

10/26/2023

Incidence and Characteristics of Akathisia With Adjunctive Cariprazine Treatment in Patients With Major Depressive Disorder

Incidence of akathisia was higher for cariprazine than placebo, with lower incidence observed for patients treated with cariprazine 1.5mg/d+ADT versus 3mg/d+ADT, suggesting dose related e...

Majid Kerolous , PharmD, MPH;

10/26/2023

Implementation of Exercise Reminders to Improve Symptoms of Clinical Depression

This poster is part of the requirement in fulfillment of a Doctor of Nursing Practice (DNP) degree at Rutgers University, School of Nursing. The purpose of the project is to improve the s...

Femi R. Omidire , APN, PHMNP-BC;

10/26/2023

Improvements in Cognitive and Physical Functioning Outcomes in Depressed Patients Treated with AXS-05 (Dextromethorphan-Bupropion): Results from the EVOLVE Open-Label, Long-Term Study

AXS-05 exhibited rapid and sustained improvements in cognitive and physical functioning in individuals with MDD who previously tried one or more prior antidepressants. This study also sho...

Shawn Alter , PhD;

10/26/2023

Healthcare Resource Utilization and Costs of Using Cariprazine as the First Versus Subsequent Adjunctive Therapy for Major Depressive Disorder

Adjunctive therapy with atypical antipsychotics is a treatment option for patients diagnosed with major depressive disorder and inadequate response to antidepressant monotherapy. This cla...

10/26/2023

Impact of Adjunctive Cariprazine on Quality of Life in Major Depressive Disorder: A Post Hoc Analysis

Patients with major depressive disorder often have reduced quality of life. A previous phase 3 trial showed cariprazine adjunctive to antidepressant therapy reduces depressive symptoms in...

10/26/2023

Impact of AXS-05 (Dextromethorphan-Bupropion) on Patient-Reported Insomnia Symptoms: Results from the GEMINI Trial

In GEMINI, AXS-05, an oral NMDA receptor antagonist approved for MDD, showed significantly higher response rates (defined as 50% reduction in QIDS insomnia score) starting at Week 3 throu...

William Olsufka , PharmD;

10/26/2023

Evaluation of Mania and Hypomania in Late-Phase Clinical Trials of Lumateperone in the Treatment of Major Depressive Episodes Associated With Bipolar I or Bipolar II Disorder

This analysis evaluated mania and hypomania across 2 pooled, 6-week, placebo-controlled monotherapy studies; a 6-month open-label extension (OLE) monotherapy study; and a 6-week, placebo-...

Tobie Escher , PhD;

10/26/2023

Head-To-Head Comparison of Vortioxetine Versus Desvenlafaxine in Patients With Major Depressive Disorder With Partial Response to Selective Serotonin Reuptake Inhibitors: The VIVRE Study

This study assessed the efficacy of vortioxetine versus desvenlafaxine in patients with MDD experiencing partial response to treatment with an SSRI. Vortioxetine was noninferior to desven...

Michael C. Fischi , MD;

10/26/2023